Diabetes
Metabolic 16 original drugs 16
Novel Drugs
16
Reformulations
0
Active Trials
6
Drug Targets
Market Leaders
Phase 3 Readouts Pro
11 active Phase 3 trials with confidence-graded completion dates.
Q4 2026
Exendin-4 Fc fusion protein injection(1.2mg）
Beijing Dongfang Biotech Co., Ltd.
Estimated · aging NCT06257966
Unlock 8 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 180 industry trials with a known mechanism of action.
Sodium-Glucose Cotransporter 2 Inhibitor
6 trials 1 active 2 sponsors
GLP-1 Receptor Agonist
86 trials 3 sponsors
Insulin Analog
68 trials 7 sponsors
SGLT2
6 trials 1 sponsor
Dipeptidyl Peptidase 4 Inhibitor
6 trials 3 sponsors
DPP-4
2 trials 1 sponsor
Corticosteroid
1 trials 1 sponsor
amylases/lipases/proteases
1 trials 1 sponsor
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
1 trials 1 sponsor
PCSK9 Inhibitor
1 trials 1 sponsor
Vascular Endothelial Growth Factor Inhibitor
1 trials 1 sponsor
Cytochrome a3/Hemoglobin
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
818 industry-sponsored trials across 206 sponsors
Showing 75 of 75 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Getz Pharma | Empagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | RECRUITING | 2026-12-31 | NCT05164263 |
| Nabiqasim Industries (Pvt) Ltd | — | — | RECRUITING | 2026-04-30 | NCT06862739 |
| Dong Wha Pharmaceutical Co. Ltd. | DW6012(Dasidiem tab. 10/100mg) | — | RECRUITING | 2025-12-31 | NCT06875193 |
| Les Laboratoires des Médicaments Stériles | switch NPH to glargin | — | NOT YET RECRUITING | 2025-12-31 | NCT06999551 |
| Dong-A ST Co., Ltd. | DA-2811 | — | COMPLETED | 2025-03-10 | NCT05743907 |
| Johnson & Johnson Private Limited | Canagliflozin + Metformin hydrochloride (Fixed Dose Combination) | — | COMPLETED | 2022-07-26 | NCT04288778 |
| Getz Pharma | Empagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2020-09-15 | NCT04665284 |
| Dong-A ST Co., Ltd. | Evogliptin | — | COMPLETED | 2020-07-02 | NCT03910361 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2019-08-05 | NCT02730377 |
| Yuhan Corporation | Rosuvastatin+Ezetimibe | — | COMPLETED | 2019-04-03 | NCT03217409 |
| AstraZeneca | dapagliflozin | SGLT2 | COMPLETED | 2019-03-19 | NCT03387683 |
| Sanofi | INSULIN GLARGINE (U300) | — | COMPLETED | 2019-02-04 | NCT03406000 |
| Handok Inc. | Teneligliptin | — | COMPLETED | 2018-09 | NCT03011177 |
| Dong-A ST Co., Ltd. | evogliptin | — | COMPLETED | 2018-03 | NCT02974504 |
| GSK | Albiglutide 30 mg | — | COMPLETED | 2018-02-20 | NCT02465515 |
| AstraZeneca | — | — | COMPLETED | 2017-12-20 | NCT02910089 |
| Novo Nordisk | — | — | COMPLETED | 2017-12-09 | NCT02617693 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2017-03-18 | NCT02582242 |
| Takeda | Pioglitazone | — | COMPLETED | 2016-10-17 | NCT01972724 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2016-09-20 | NCT02453685 |
| Prof. Dr. Thomas Forst | Saxagliptin | — | COMPLETED | 2016-08 | NCT02304081 |
| Materia Medica Holding | Subetta | — | COMPLETED | 2016-07 | NCT01868594 |
| Materia Medica Holding | Subetta | — | COMPLETED | 2016-06-15 | NCT01868646 |
| Profil Institut für Stoffwechselforschung GmbH | Linagliptin | Dipeptidyl Peptidase 4 Inhibitor [EPC] | COMPLETED | 2016-04 | NCT01903070 |
| LifeScan | — | — | COMPLETED | 2016-04 | NCT02429024 |
| Novartis | LAF237 (vildagliptin) | — | COMPLETED | 2015-10-22 | NCT01766778 |
| AstraZeneca | Farxiga | SGLT2 | COMPLETED | 2015-10 | NCT02429258 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2015-07-09 | NCT01589653 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-06-15 | NCT01907854 |
| Novo Nordisk | insulin detemir | — | COMPLETED | 2015-05 | NCT01868542 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2014-11 | NCT02008682 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2014-11 | NCT01973231 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2014-09-01 | NCT01917656 |
| Novartis | Vildagliptin | — | COMPLETED | 2014-09 | NCT01686932 |
| Chemical Resources | — | — | COMPLETED | 2014-05 | NCT02700477 |
| AstraZeneca | Saxagliptin | — | COMPLETED | 2014-05 | NCT01608724 |
| Novo Nordisk | biphasic insulin aspart 50 | — | COMPLETED | 2014-05 | NCT01892020 |
| Profil Institut für Stoffwechselforschung GmbH | — | — | COMPLETED | 2014-01 | NCT01730885 |
| Takeda | AD-4833 15 mg | — | COMPLETED | 2013-12 | NCT01686711 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2013-10 | NCT01519674 |
| Abbott Diabetes Care | — | — | COMPLETED | 2013-05 | NCT01713348 |
| Merck KGaA, Darmstadt, Germany | Bisoprolol | — | COMPLETED | 2013-04 | NCT01066039 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2013-01 | NCT01618214 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2012-09 | NCT01215435 |
| Novartis | vildagliptin | — | COMPLETED | 2012-08 | NCT00894868 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2012-07 | NCT01427920 |
| Novartis | Vildagliptin | — | COMPLETED | 2012-06 | NCT01398592 |
| Novo Nordisk | insulin detemir | — | COMPLETED | 2012-05 | NCT01068652 |
| Novo Nordisk | insulin aspart | Insulin Analog [EPC] | COMPLETED | 2012-04 | NCT01165684 |
| Novo Nordisk | Insulin detemir | — | COMPLETED | 2011-11-01 | NCT01232491 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2011-09 | NCT01278160 |
| Vantive Health LLC | Physioneal | — | COMPLETED | 2011-07 | NCT00567489 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2011-06 | NCT01123980 |
| Takeda | Pioglitazone and Metformin | — | COMPLETED | 2011-05 | NCT00770835 |
| Novo Nordisk | Insulin-Levemir | — | COMPLETED | 2011-04 | NCT01076842 |
| Novo Nordisk | repaglinide | — | COMPLETED | 2010-11 | NCT01022762 |
| Novo Nordisk | insulin detemir | — | COMPLETED | 2010-08 | NCT00795600 |
| Takeda | Pioglitazone and insulin | — | COMPLETED | 2010-07 | NCT00770445 |
| Novo Nordisk | insulin detemir | — | COMPLETED | 2010-06 | NCT00909480 |
| Novartis | Amlodipine | — | COMPLETED | 2010-01 | NCT00787605 |
| Novo Nordisk | repaglinide | — | COMPLETED | 2009-11 | NCT00819741 |
| Merck | sitagliptin phosphate | DPP-4 | COMPLETED | 2009-10-30 | NCT00833027 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2009-10 | NCT00807092 |
| Novo Nordisk | insulin detemir | — | COMPLETED | 2008-10 | NCT00634842 |
| GSK | Albiglutide 50mg | — | TERMINATED | 2017-08-10 | NCT02802514 |
| Novo Nordisk | insulin detemir | — | TERMINATED | 2012-06 | NCT01486966 |
| Novartis | Valturna | — | TERMINATED | 2012-02 | NCT01368536 |
| Merck | sitagliptin | Dipeptidyl Peptidase 4 Inhibitor [EPC] | TERMINATED | 2009-09-02 | NCT00832624 |
| Bracco Diagnostics, Inc | Iopamidol injection 76% | — | TERMINATED | 2009-09 | NCT00782639 |
| Ascension Health | Dexamethasone | Corticosteroid [EPC] | WITHDRAWN | 2020-12-31 | NCT03646916 |
| AstraZeneca | Dapagliflozin | SGLT2 | WITHDRAWN | 2017-11 | NCT02719132 |
| Abbott | Creon | amylases/lipases/proteases | WITHDRAWN | 2014-08 | NCT02009410 |
| LifeScan | — | — | WITHDRAWN | 2013-06 | NCT01631643 |
| Merck KGaA, Darmstadt, Germany | Glucophage | — | WITHDRAWN | 2012-06 | NCT01510522 |
| Medtronic - MITG | — | — | WITHDRAWN | 2009-01 | NCT00596973 |
Showing 100 of 234 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| EMS | PIEMONTE | — | RECRUITING | 2026-07 | NCT05028140 |
| Gan & Lee Pharmaceuticals. | GZR4 | — | RECRUITING | 2026-11-10 | NCT07165223 |
| Pfizer | PF-08653944 | — | RECRUITING | 2027-10-12 | NCT07400653 |
| Kailera | KAI-9531 | — | RECRUITING | 2028-03-27 | NCT07284901 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2028-08-07 | NCT07533175 |
| Khondrion BV | Sonlicromanol | — | RECRUITING | 2028-09 | NCT06451757 |
| EMS | BERLIM 25/20 ASSOCIATION | — | RECRUITING | 2026-05 | NCT04602754 |
| Energenesis Biomedical Co., Ltd. | ENERGI-F703 GEL | — | RECRUITING | 2025-12-30 | NCT05930210 |
| Gan & Lee Pharmaceuticals. | GZR4 | — | ACTIVE NOT RECRUITING | 2026-08-01 | NCT06767735 |
| Beijing Dongfang Biotech Co., Ltd. | Exendin-4 Fc fusion protein injection(1.2mg） | — | ACTIVE NOT RECRUITING | 2026-10-01 | NCT06257966 |
| Gan & Lee Pharmaceuticals. | GZR4 | — | ACTIVE NOT RECRUITING | 2026-03-19 | NCT06767761 |
| Gan & Lee Pharmaceuticals. | GZR4 | — | ACTIVE NOT RECRUITING | 2026-02-07 | NCT06767748 |
| HK inno.N Corporation | IN-B00009 | — | NOT YET RECRUITING | 2027-08 | NCT07308184 |
| Eli Lilly | Retatrutide | — | COMPLETED | 2026-01-22 | NCT06354660 |
| Novo Nordisk | Insulin icodec | — | COMPLETED | 2025-05-08 | NCT06340854 |
| Sunshine Lake Pharma Co., Ltd. | Insulin Degludec and Insulin Aspart | — | COMPLETED | 2024-08-16 | NCT05802862 |
| Eli Lilly | Tirzepatide Dose 1 | — | COMPLETED | 2024-07-30 | NCT05260021 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | COMPLETED | 2024-07-01 | NCT05691712 |
| Eli Lilly | Insulin Efsitora Alfa | — | COMPLETED | 2024-05-07 | NCT05463744 |
| Eli Lilly | Insulin Efsitora Alfa | — | COMPLETED | 2024-04-10 | NCT05362058 |
| AJU Pharm Co., Ltd. | AJU-A51 | — | COMPLETED | 2022-12-01 | NCT06329674 |
| Eli Lilly | Dulaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2022-10-01 | NCT04809220 |
| Boryung Pharmaceutical Co., Ltd | Metformin≥1000mg | — | COMPLETED | 2022-09-19 | NCT04885712 |
| Dong-A ST Co., Ltd. | Evogliptin 5mg | — | COMPLETED | 2021-06-28 | NCT04170998 |
| Novo Nordisk | Insulin degludec | Insulin Analog [EPC] | COMPLETED | 2020-12-17 | NCT03377699 |
| Chong Kun Dang Pharmaceutical | CKD-501 0.5mg | — | COMPLETED | 2020-05-25 | NCT03739125 |
| Geropharm | GP40071 | — | COMPLETED | 2020-01-21 | NCT04079413 |
| Merck | Sitagliptin | Dipeptidyl Peptidase 4 Inhibitor [EPC] | COMPLETED | 2019-10-09 | NCT01485614 |
| Novo Nordisk | Insulin degludec/liraglutide | — | COMPLETED | 2019-06-14 | NCT03172494 |
| Valbiotis | — | — | COMPLETED | 2019-04 | NCT02868177 |
| Novo Nordisk | Semaglutide 0.5 mg | — | COMPLETED | 2019-03-14 | NCT03061214 |
| Novo Nordisk | Insulin degludec/liraglutide | — | COMPLETED | 2019-03-05 | NCT03175120 |
| Geropharm | Lantus Solostar, 100 Units/mL Subcutaneous Solution | — | COMPLETED | 2019-02-25 | NCT04022993 |
| Novo Nordisk | Insulin degludec | Insulin Analog [EPC] | COMPLETED | 2019-02-13 | NCT03078478 |
| Biocon Limited | Insulin Tregopil | — | COMPLETED | 2019-02-06 | NCT03430856 |
| Theracos | Bexagliflozin tablets, 20 mg | — | COMPLETED | 2019-01-23 | NCT03259789 |
| Geropharm | Humalog Mix25 | — | COMPLETED | 2019-01-15 | NCT04023344 |
| Novo Nordisk | Faster-acting insulin aspart | — | COMPLETED | 2019-01-07 | NCT03268005 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-10-16 | NCT03136484 |
| Novo Nordisk | insulin degludec/liraglutide | — | COMPLETED | 2018-10-03 | NCT02501161 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-09-25 | NCT02692716 |
| AstraZeneca | Dapagliflozin 10 mg | — | COMPLETED | 2018-09-11 | NCT01730534 |
| Eli Lilly | LY900014 | — | COMPLETED | 2018-09-04 | NCT03433677 |
| Eli Lilly | Glucagon Nasal Powder | — | COMPLETED | 2018-08-20 | NCT03421379 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-07-12 | NCT03015220 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-07-09 | NCT03191396 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-07-04 | NCT03086330 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-05-04 | NCT02964247 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-04-10 | NCT02827708 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-02-28 | NCT02849080 |
| Novo Nordisk | Faster-acting insulin aspart | — | COMPLETED | 2018-02-05 | NCT02670915 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-01-18 | NCT03021187 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-01-09 | NCT03018028 |
| Novo Nordisk | insulin degludec/liraglutide | — | COMPLETED | 2017-12-15 | NCT02607306 |
| Amgen | Evolocumab | PCSK9 Inhibitor [EPC] | COMPLETED | 2017-12-06 | NCT02662569 |
| Novo Nordisk | Insulin degludec/liraglutide | — | COMPLETED | 2017-11-17 | NCT02911948 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2017-11-15 | NCT01541215 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2017-10-30 | NCT02906930 |
| Novo Nordisk | insulin degludec/liraglutide | — | COMPLETED | 2017-09-26 | NCT02773368 |
| Novo Nordisk | Insulin degludec/insulin aspart | — | COMPLETED | 2017-08-31 | NCT02906917 |
| AstraZeneca | Saxagliptin | — | COMPLETED | 2017-08-29 | NCT02419612 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2017-08-19 | NCT02863419 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2017-08-01 | NCT02863328 |
| Novo Nordisk | Faster-acting insulin aspart | — | COMPLETED | 2017-07-17 | NCT02500706 |
| Yuhan Corporation | YH14755 | — | COMPLETED | 2017-07-07 | NCT02586129 |
| Novo Nordisk | Faster-acting insulin aspart | — | COMPLETED | 2017-06-20 | NCT02825251 |
| Novo Nordisk | insulin degludec/insulin aspart | — | COMPLETED | 2017-05-19 | NCT02762578 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2017-05-02 | NCT02505334 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2017-04-10 | NCT02648204 |
| Daewoong Pharmaceutical Co. LTD. | Metformin/Atorvastatin 1500mg/40mg, QD | — | COMPLETED | 2017-02-27 | NCT02947620 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2017-02-14 | NCT02607865 |
| Dompé Farmaceutici S.p.A | Reparixin | — | COMPLETED | 2016-12 | NCT01817959 |
| Novo Nordisk | insulin degludec | Insulin Analog [EPC] | COMPLETED | 2016-10-16 | NCT01959529 |
| Novo Nordisk | insulin degludec/liraglutide | — | COMPLETED | 2016-10-05 | NCT02420262 |
| Novo Nordisk | insulin degludec/insulin aspart | — | COMPLETED | 2016-09-04 | NCT02648217 |
| AstraZeneca | Exenatide | — | COMPLETED | 2016-08-29 | NCT02229383 |
| Tonghua Dongbao Pharmaceutical Co.,Ltd | insulin Aspart injection | — | COMPLETED | 2016-08-12 | NCT02491528 |
| AstraZeneca | Exantide with Dapagliflozin | — | COMPLETED | 2016-04-26 | NCT02229396 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2016-03-15 | NCT01720446 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2016-02-27 | NCT02207374 |
| AstraZeneca | Dapagliflozin | SGLT2 | COMPLETED | 2016-01-28 | NCT02096705 |
| Novo Nordisk | insulin degludec | Insulin Analog [EPC] | COMPLETED | 2016-01-11 | NCT02034513 |
| Novo Nordisk | insulin degludec/liraglutide | — | COMPLETED | 2015-12-23 | NCT02298192 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-12-17 | NCT01179048 |
| Novo Nordisk | insulin degludec | Insulin Analog [EPC] | COMPLETED | 2015-12-04 | NCT02030600 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-11-21 | NCT02305381 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-11-11 | NCT02254291 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-10-12 | NCT01930188 |
| InQpharm Group | — | — | COMPLETED | 2015-10 | NCT02541344 |
| Merck | Omarigliptin | — | COMPLETED | 2015-09-14 | NCT01814748 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-09-03 | NCT02128932 |
| Takeda | Alogliptin | — | COMPLETED | 2015-09 | NCT01890122 |
| Eli Lilly | Nasal Glucagon | — | COMPLETED | 2015-08 | NCT02171130 |
| Eli Lilly | Nasal Glucagon | — | COMPLETED | 2015-08 | NCT02402933 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-07-13 | NCT01885208 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-06 | NCT01836523 |
| Novo Nordisk | Faster-acting insulin aspart | — | COMPLETED | 2015-05-12 | NCT01831765 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-05-08 | NCT02054897 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-04 | NCT02098395 |
| Novo Nordisk | insulin degludec/liraglutide | — | COMPLETED | 2015-04 | NCT02100475 |
Showing 100 of 165 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Op-T LLC | OPT101 | — | RECRUITING | 2026-05-31 | NCT06964087 |
| Corxel Pharmaceuticals | CX11 | — | RECRUITING | 2026-12-23 | NCT07340320 |
| Hudson Biotech | MOTS-c (MDP) | — | RECRUITING | 2027-02-14 | NCT07505745 |
| Sun Pharmaceutical Industries Limited | GL0034 Dose Level 1 | — | RECRUITING | 2027-04 | NCT07282743 |
| Otsuka Pharmaceutical Factory, Inc. | — | — | RECRUITING | 2027-06-30 | NCT06575426 |
| Thomas Advanced Medical LLC | PrimePro™/ PrimeMSK™ | — | RECRUITING | 2030-07-09 | NCT04684602 |
| PolTREG S.A. | ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) | — | RECRUITING | 2032-12 | NCT06688331 |
| Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | Fuling Yunhua Granules | — | RECRUITING | 2025-01-30 | NCT06575478 |
| Golo | — | — | RECRUITING | 2024-11 | NCT05844644 |
| AstraZeneca | AZD6234 | — | ACTIVE NOT RECRUITING | 2026-05-27 | NCT06851858 |
| Admetsys Corporation | — | — | ACTIVE NOT RECRUITING | 2026-11 | NCT01291719 |
| Xantho Biotechnology Co., LTD | GM-XANTHO | — | NOT YET RECRUITING | 2028-12-31 | NCT05199077 |
| Altheia Science | — | — | NOT YET RECRUITING | 2029-06-15 | NCT06938334 |
| Metsera, a wholly owned subsidiary of Pfizer | MET097 Injection | — | COMPLETED | 2026-01-02 | NCT06897202 |
| Unity Biotechnology, Inc. | Aflibercept | Vascular Endothelial Growth Factor Inhibitor [EPC] | COMPLETED | 2025-01-21 | NCT06011798 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | GSBR-1290 | — | COMPLETED | 2024-04-11 | NCT05762471 |
| Aphaia Pharma US LLC | APHD-012 | — | COMPLETED | 2024-02-12 | NCT05803772 |
| Oxurion | THR-149 dose level 1 | — | COMPLETED | 2023-09-28 | NCT04527107 |
| Khondrion BV | Oral administration of 100 mg KH176 twice daily | — | COMPLETED | 2023-06-01 | NCT04604548 |
| WinSanTor, Inc | Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution | — | COMPLETED | 2022-12-08 | NCT04786340 |
| Bayer | BAY2395840 | — | COMPLETED | 2022-11-07 | NCT05219812 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Polysaccharide superparamagnetic iron oxide injection | — | COMPLETED | 2022-06-13 | NCT06051565 |
| Lexicon Pharmaceuticals | LX9211 | — | COMPLETED | 2022-05-23 | NCT04455633 |
| CuraLife | — | — | COMPLETED | 2022-04-01 | NCT05439473 |
| Youngene Therapeutics Inc., Ltd. | YG1699 | — | COMPLETED | 2022-02-02 | NCT04956263 |
| Novartis | Inclisiran | — | COMPLETED | 2021-12-17 | NCT03060577 |
| Pfizer | PF-06882961 | — | COMPLETED | 2021-11-17 | NCT04617275 |
| Precigen Actobio T1D, LLC | AG019 - Low Dose | — | COMPLETED | 2021-10-13 | NCT03751007 |
| REMD Biotherapeutics, Inc. | REMD-477 | — | COMPLETED | 2021-03-05 | NCT03117998 |
| NextCell Pharma Ab | ProTrans | — | COMPLETED | 2020-12-10 | NCT03973827 |
| Neuraly, Inc. | NLY01 | — | COMPLETED | 2020-12-04 | NCT04159766 |
| Diamyd Medical AB | Diamyd | — | COMPLETED | 2020-07-13 | NCT03345004 |
| NextCell Pharma Ab | ProTrans: Allogeneic transplantation with WJMSCs | — | COMPLETED | 2020-07-01 | NCT03406585 |
| Xeris Pharmaceuticals | PRAM9 | — | COMPLETED | 2020-04-02 | NCT04074317 |
| Oramed, Ltd. | Oral Insulin | — | COMPLETED | 2020-03-01 | NCT02653300 |
| Charsire Biotechnology Corp. | CSTC1 | — | COMPLETED | 2020-01-07 | NCT01813305 |
| MedImmune LLC | MEDI0382 | — | COMPLETED | 2019-12-22 | NCT03596177 |
| Eli Lilly | LY900014 | — | COMPLETED | 2019-10-07 | NCT03760640 |
| Energenesis Biomedical Co., Ltd. | ENERGI-F703 | — | COMPLETED | 2019-10-03 | NCT02672436 |
| Boston Therapeutics | BTI320 | — | COMPLETED | 2019-08-30 | NCT03655535 |
| Oxurion | Ranibizumab 0.5mg | — | COMPLETED | 2019-07-18 | NCT03499223 |
| Esperion Therapeutics, Inc. | Bempedoic acid + Ezetimibe FDC Oral Tablet | — | COMPLETED | 2019-06-18 | NCT03531905 |
| Dompé Farmaceutici S.p.A | Ladarixin | — | COMPLETED | 2019-05-15 | NCT02814838 |
| Sanofi | Sotagliflozin (SAR439954) | — | COMPLETED | 2019-04-18 | NCT03462069 |
| Lisata Therapeutics, Inc. | CLBS03 Low Dose | — | COMPLETED | 2019-03 | NCT02691247 |
| MedImmune LLC | MEDI0382 | — | COMPLETED | 2019-02-04 | NCT03550378 |
| GeNeuro Australia PTY Ltd | GNbAC1 | — | COMPLETED | 2018-09-01 | NCT03179423 |
| Novo Nordisk | NNC0114-0006 | — | COMPLETED | 2018-08-31 | NCT02443155 |
| AbbVie | Atrasentan | — | COMPLETED | 2018-04-18 | NCT02118714 |
| Millennium Pharmaceuticals, Inc. | TAK-906 Maleate | — | COMPLETED | 2018-03-09 | NCT03268941 |
| Diasome Pharmaceuticals | HDV insulin lispro 100 UNIT/mL | — | COMPLETED | 2018-01-15 | NCT03156361 |
| REMD Biotherapeutics, Inc. | REMD-477 | — | COMPLETED | 2018-01 | NCT02455011 |
| Liminal BioSciences Ltd. | PBI-4050 | — | COMPLETED | 2017-09-26 | NCT02739217 |
| The Medicines Company | ALN-PCSSC | — | COMPLETED | 2017-06-07 | NCT02597127 |
| NovMetaPharma Co., Ltd. | Cyclo-Z | — | COMPLETED | 2017-05-03 | NCT02784275 |
| Zealand Pharma | ZP4207(dasiglucagon) glucagon analogue | — | COMPLETED | 2017-04-05 | NCT02916251 |
| Kamada, Ltd. | Alpha-1 Antitrypsin | — | COMPLETED | 2017-02 | NCT02005848 |
| Oshadi Drug Administration | Oshadi Icp | — | COMPLETED | 2017-02 | NCT01973920 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2016-10-13 | NCT02461589 |
| Astellas Pharma Europe B.V. | ASP8232 | — | COMPLETED | 2016-08-12 | NCT02302079 |
| Oramed, Ltd. | ORMD-0801 | — | COMPLETED | 2016-06-27 | NCT02496000 |
| AbbVie | Relamorelin | — | COMPLETED | 2016-06-09 | NCT02357420 |
| Novo Nordisk | insulin 338 (GIPET I) | — | COMPLETED | 2015-12-31 | NCT02470039 |
| TheraVasc Inc. | Sodium nitrite | Cytochrome a3/Hemoglobin | COMPLETED | 2015-12-07 | NCT02412852 |
| AstraZeneca | Omega-3 carboxylic acids | — | COMPLETED | 2015-12 | NCT02279407 |
| Bristol-Myers Squibb | BMS-986036 | — | COMPLETED | 2015-09-22 | NCT02097277 |
| Novo Nordisk | Liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2015-09-15 | NCT02205528 |
| BioDelivery Sciences International | clonidine hydrochloride topical gel, 0.1% | — | COMPLETED | 2015-08 | NCT02355158 |
| ANS Pharma | Diacerein | — | COMPLETED | 2015-08 | NCT03208309 |
| Pfizer | PF-06291874 | — | COMPLETED | 2015-03 | NCT02175121 |
| Osprey Medical, Inc | Timentin | — | COMPLETED | 2015-02 | NCT02158442 |
| Tris Pharma, Inc. | Cebranopadol 100 µg | — | COMPLETED | 2015-01 | NCT01939366 |
| Yuhan Corporation | YH14617 | — | COMPLETED | 2015-01 | NCT01507038 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2014-12-11 | NCT01923181 |
| Adocia | BioChaperone human insulin | — | COMPLETED | 2014-12 | NCT02213146 |
| Biodel | BIOD-531 | — | COMPLETED | 2014-11 | NCT02324309 |
| Profil Institut für Stoffwechselforschung GmbH | Insulin LISPRO | Insulin Analog [EPC] | COMPLETED | 2014-11 | NCT02221323 |
| Profil Institut für Stoffwechselforschung GmbH | Luyxumia versus Lantus | — | COMPLETED | 2014-10 | NCT01910194 |
| NGM Biopharmaceuticals, Inc | NGM282 | — | COMPLETED | 2014-09 | NCT01943045 |
| DiaMedica Therapeutics Inc | DM199 | — | COMPLETED | 2014-09 | NCT01845064 |
| Oramed, Ltd. | ORMD-0801 Capsules | — | COMPLETED | 2014-08 | NCT02094534 |
| Adocia | BioChaperone insulin lispro 0.2U/Kg | — | COMPLETED | 2014-07 | NCT02146651 |
| Resverlogix Corp | RVX000222 | — | COMPLETED | 2014-03 | NCT01728467 |
| DIApedia, LLC | — | — | COMPLETED | 2013-12 | NCT00803608 |
| Theracos | EGT0001442 | — | COMPLETED | 2013-11 | NCT01377844 |
| Oramed, Ltd. | ORMD-0801 Dose # 1 | — | COMPLETED | 2013-11 | NCT01889667 |
| Novartis | Sitagliptin | Dipeptidyl Peptidase 4 Inhibitor [EPC] | COMPLETED | 2013-09 | NCT01619332 |
| GSK | GSK1070806 | — | COMPLETED | 2013-09 | NCT01648153 |
| Roche | aleglitazar | — | COMPLETED | 2013-09 | NCT01729403 |
| Roche | aleglitazar | — | COMPLETED | 2013-09 | NCT01680978 |
| Motus Therapeutics, Inc. | RM-131 | — | COMPLETED | 2013-08 | NCT01571297 |
| Hanmi Pharmaceutical Company Limited | HM11260C | — | COMPLETED | 2013-06 | NCT01452451 |
| Oshadi Drug Administration | Oshadi Icp | — | COMPLETED | 2013-06 | NCT01772251 |
| Amgen | AMG 151 | — | COMPLETED | 2012-10 | NCT01464437 |
| Cebix Incorporated | CBX129801 | — | COMPLETED | 2012-08 | NCT01293461 |
| Roche | aleglitazar | — | COMPLETED | 2012-07 | NCT01043029 |
| Becton, Dickinson and Company | — | — | COMPLETED | 2012-05 | NCT01557907 |
| Pfizer | 150 mg PF-04991532 | — | COMPLETED | 2012-03 | NCT01336738 |
| Ascension Health | — | — | COMPLETED | 2012-01 | NCT01354262 |
| Evoke Pharma | metoclopramide | — | COMPLETED | 2011-12 | NCT00845858 |
Showing 100 of 344 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Boryung Pharmaceutical Co., Ltd | Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg | — | RECRUITING | 2026-07-03 | NCT07083388 |
| Sun Pharmaceutical Industries Limited | GL0034 | — | RECRUITING | 2026-09 | NCT07385547 |
| Eli Lilly | Retatrutide | — | RECRUITING | 2026-11 | NCT06982859 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-3167 Injection | — | RECRUITING | 2026-12 | NCT07489482 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2027-11-11 | NCT07535307 |
| Hangzhou Reprogenix Bioscience, Inc | RGB-5088 | — | RECRUITING | 2027-12-31 | NCT06731218 |
| Rezubio Pharmaceuticals Co., Ltd. | RZ-629 | — | RECRUITING | 2025-12-20 | NCT06829563 |
| Jiangsu HengRui Medicine Co., Ltd. | HR011408 injection; HR011408 injection Placebo | — | RECRUITING | 2024-07-01 | NCT06375031 |
| Gan & Lee Pharmaceuticals. | GZR4 | — | ACTIVE NOT RECRUITING | 2026-07-14 | NCT07193147 |
| Korea United Pharm. Inc. | Administration of UI087 | — | NOT YET RECRUITING | 2026-08 | NCT07548957 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 Injection | — | NOT YET RECRUITING | 2027-01 | NCT07540754 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | NDI-5001 | — | NOT YET RECRUITING | 2027-04-14 | NCT07525960 |
| Immunocore Ltd | IMC-S118AI | — | NOT YET RECRUITING | 2030-11 | NCT07493122 |
| Addpharma Inc. | AD-123 | — | NOT YET RECRUITING | 2026-05 | NCT07538466 |
| AJU Pharm Co., Ltd. | Comparator 1 | — | NOT YET RECRUITING | 2025-11 | NCT07044765 |
| AJU Pharm Co., Ltd. | Comparator 1 | — | NOT YET RECRUITING | 2025-11 | NCT07034781 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 Tables | — | COMPLETED | 2026-01-22 | NCT06961643 |
| Vivani Medical, Inc | Bydureon BCise (exenatide extended release) | — | COMPLETED | 2025-08-21 | NCT05670379 |
| Lexaria Bioscience Corp. | Arm 1 - DehydraTECH-CBD alone | — | COMPLETED | 2025-07-31 | NCT06648031 |
| Gedeon Richter Plc. | Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated tablets | — | COMPLETED | 2025-05-21 | NCT06823856 |
| Gedeon Richter Plc. | Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets | — | COMPLETED | 2025-04-06 | NCT06792968 |
| Gedeon Richter Plc. | Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets | — | COMPLETED | 2025-02-28 | NCT06766500 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 tablets | — | COMPLETED | 2025-01-25 | NCT06727838 |
| Zhejiang Anglikang Pharmaceutical Co., Ltd. | BM2216 Extended-Release tablets（5.5mg） | — | COMPLETED | 2025-01-04 | NCT06846567 |
| Chong Kun Dang Pharmaceutical | CKD-379 | — | COMPLETED | 2024-12-04 | NCT06652971 |
| Tonghua Dongbao Pharmaceutical Co.,Ltd | THDBH120 injection | — | COMPLETED | 2024-11-27 | NCT07020949 |
| Hua Medicine Limited | HM-002-1005 | — | COMPLETED | 2024-09-06 | NCT06498284 |
| Gan and Lee Pharmaceuticals, USA | GZR4 | — | COMPLETED | 2024-08-20 | NCT06547502 |
| Carmot Therapeutics, Inc. | CT-388 | — | COMPLETED | 2024-06-18 | NCT04838405 |
| Huons Co., Ltd. | HUC2-344 | — | COMPLETED | 2024-06-10 | NCT06551740 |
| Chong Kun Dang Pharmaceutical | CKD-378, QD, PO | — | COMPLETED | 2024-06-03 | NCT06386328 |
| Atrogi AB | ATR-258 Oral solution | — | COMPLETED | 2024-05-27 | NCT06432673 |
| Boryung Pharmaceutical Co., Ltd | BR3005 | — | COMPLETED | 2024-04-03 | NCT06289933 |
| Huons Co., Ltd. | HUC2-344 | — | COMPLETED | 2024-02-15 | NCT06552182 |
| Humanis Saglık Anonim Sirketi | Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets | — | COMPLETED | 2024-01-16 | NCT06450262 |
| Gan and Lee Pharmaceuticals, USA | GZR4 | — | COMPLETED | 2023-11-01 | NCT06553248 |
| Jiangsu HengRui Medicine Co., Ltd. | HR011408 injection; NovoRapid® | — | COMPLETED | 2023-10-26 | NCT05737576 |
| Boryung Pharmaceutical Co., Ltd | BR3006-1 | — | COMPLETED | 2023-09-11 | NCT05951946 |
| Chong Kun Dang Pharmaceutical | CKD-378, QD, PO Drug: D745, D150, QD, PO | — | COMPLETED | 2023-08-31 | NCT05741437 |
| Chong Kun Dang Pharmaceutical | D745, D759, D150 | — | COMPLETED | 2023-08-29 | NCT05928637 |
| Humanis Saglık Anonim Sirketi | Empagliflozin film coated tablets | — | COMPLETED | 2023-08-27 | NCT06180109 |
| Jiangsu HengRui Medicine Co., Ltd. | INS062 injection、INS068 injection、HR20014 injection | — | COMPLETED | 2023-07-18 | NCT05887895 |
| Chong Kun Dang Pharmaceutical | CKD-378 (low-dose) | — | COMPLETED | 2023-06-28 | NCT05881213 |
| Vicore Pharma AB | C21 | — | COMPLETED | 2023-06-16 | NCT05831644 |
| Gan and Lee Pharmaceuticals, USA | GZR4 | — | COMPLETED | 2023-03-24 | NCT06548815 |
| Chong Kun Dang Pharmaceutical | CKD-379 | — | COMPLETED | 2023-03-23 | NCT05719155 |
| CRISPR Therapeutics AG | — | — | COMPLETED | 2023-01-19 | NCT05210530 |
| Neuraly, Inc. | DD01 | — | COMPLETED | 2022-12-20 | NCT04812262 |
| AstraZeneca | Experimental: Cotadutide | — | COMPLETED | 2022-12-12 | NCT05437848 |
| CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | TG103 injection | — | COMPLETED | 2022-12-01 | NCT04855292 |
| Chong Kun Dang Pharmaceutical | CKD-371 | — | COMPLETED | 2022-11-14 | NCT05544214 |
| Chong Kun Dang Pharmaceutical | CKD-379 I | — | COMPLETED | 2022-08-27 | NCT05452525 |
| Youngene Therapeutics Inc., Ltd. | YG1699 | — | COMPLETED | 2022-08-12 | NCT05089617 |
| Chong Kun Dang Pharmaceutical | CKD-393 | — | COMPLETED | 2022-07-15 | NCT05274880 |
| Jiangsu HengRui Medicine Co., Ltd. | INS068 injection | — | COMPLETED | 2022-05-26 | NCT05336071 |
| Retinset SL | Bosentan | ETA/ETB | COMPLETED | 2022-05-20 | NCT04068272 |
| Chong Kun Dang Pharmaceutical | CKD-393(2) | — | COMPLETED | 2022-05-02 | NCT05347576 |
| Carmot Therapeutics, Inc. | CT-868 as SC Injection | — | COMPLETED | 2022-04-22 | NCT04973111 |
| Sparrow Pharmaceuticals | SPI-62 | — | COMPLETED | 2022-03-10 | NCT05409027 |
| Goldfinch Bio, Inc. | GFB-024 | — | COMPLETED | 2022-02-08 | NCT04880291 |
| Pfizer | PF-07081532 | — | COMPLETED | 2021-07-14 | NCT04305587 |
| Chong Kun Dang Pharmaceutical | CKD-501, D745, D150 | — | COMPLETED | 2021-05-20 | NCT04810676 |
| Immunomolecular Therapeutics, Inc. | 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | — | COMPLETED | 2021-05-11 | NCT04625595 |
| Chong Kun Dang Pharmaceutical | CKD-393 formulation I | — | COMPLETED | 2021-04-22 | NCT04768673 |
| Sichuan Haisco Pharmaceutical Group Co., Ltd | [14C]HSK7653 | — | COMPLETED | 2021-01-14 | NCT04540016 |
| Richmond Research Institute | Moxifloxacin | — | COMPLETED | 2020-12-31 | NCT01984827 |
| Hanmi Pharmaceutical Company Limited | HM15136 | — | COMPLETED | 2020-12-09 | NCT04167553 |
| ThromboGenics | THR-687 dose level 1 | — | COMPLETED | 2019-11-20 | NCT03666923 |
| Jiangsu HengRui Medicine Co., Ltd. | Hydrochlorothiazide、Henagliflozin Proline | — | COMPLETED | 2019-10-10 | NCT06083116 |
| Chong Kun Dang Pharmaceutical | Part A, Reference (D635 10/500mg, Astrazeneca) | — | COMPLETED | 2019-08-30 | NCT04156685 |
| Sanofi | Sotagliflozin (SAR439954) | — | COMPLETED | 2019-08-19 | NCT03909451 |
| DiaMedica Therapeutics Inc | DM199 | — | COMPLETED | 2019-07-21 | NCT03795389 |
| Gan and Lee Pharmaceuticals, USA | Gan & Lee Insulin Lispro Injection | — | COMPLETED | 2019-07-03 | NCT04235439 |
| Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SY-009 | — | COMPLETED | 2019-05-30 | NCT04119947 |
| Stratatech, a Mallinckrodt Company | ExpressGraft-C9T1 Skin Tissue | — | COMPLETED | 2019-05-28 | NCT02657876 |
| ThromboGenics | THR-149 dose level 1 | — | COMPLETED | 2019-05-22 | NCT03511898 |
| Dong-A ST Co., Ltd. | DA-1229_01(A), Sugamet SR Tab 5/1000mg® | — | COMPLETED | 2019-04-04 | NCT03939143 |
| Dong-A ST Co., Ltd. | DA-1229_01(A), Sugamet SR Tab 5/1000mg® | — | COMPLETED | 2019-03-25 | NCT03944200 |
| Boryung Pharmaceutical Co., Ltd | Treatment A (Fimasartan, Linagliptin) | — | COMPLETED | 2019-03-04 | NCT03609294 |
| Jeil Pharmaceutical Co., Ltd. | "Metformin" and "Rosuvastatin" seperately | — | COMPLETED | 2019-02-01 | NCT03690778 |
| Dong-A ST Co., Ltd. | Evogliptin→Evogliptin+Empagliflozin→Empagliflozin | — | COMPLETED | 2019-01-18 | NCT03766724 |
| Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SY-008 | — | COMPLETED | 2018-12-30 | NCT03462589 |
| Theracos | Bexagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2018-12-26 | NCT03557658 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-10-19 | NCT02773381 |
| Chong Kun Dang Pharmaceutical | D308, CKD-501 | — | COMPLETED | 2018-09-17 | NCT03616392 |
| Novo Nordisk | Semaglutide 0.5 mg | — | COMPLETED | 2018-07-10 | NCT03288740 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-07-10 | NCT03466567 |
| Novo Nordisk | Faster aspart | — | COMPLETED | 2018-07-05 | NCT03407599 |
| Genexine, Inc. | Gx-G6 | — | COMPLETED | 2018-06-06 | NCT03651466 |
| Novo Nordisk | NNC9204-1513 | — | COMPLETED | 2018-05-24 | NCT03444467 |
| Sanofi | Sotagliflozin (SAR439954) | — | COMPLETED | 2018-03-10 | NCT03414723 |
| Eli Lilly | Insulin Lispro | Insulin Analog [EPC] | COMPLETED | 2018-02-09 | NCT03367390 |
| Novo Nordisk | insulin degludec/liraglutide | — | COMPLETED | 2018-01-02 | NCT03292185 |
| Novo Nordisk | Faster-acting insulin aspart | — | COMPLETED | 2017-12-21 | NCT02933853 |
| Novo Nordisk | Insulin icodec | — | COMPLETED | 2017-12-12 | NCT02964104 |
| VitNovo, Inc. | DCB-DM101 | — | COMPLETED | 2017-12 | NCT03033433 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2017-11-24 | NCT02877355 |
| Novo Nordisk | Faster-acting insulin aspart | — | COMPLETED | 2017-11-20 | NCT03215498 |
| Hengrui Therapeutics, Inc. | HTI-2088 | — | COMPLETED | 2017-10-23 | NCT03203811 |
| Adocia | BioChaperone® insulin lispro | — | COMPLETED | 2017-09-27 | NCT03179332 |
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Diabetes
Novel Drugs by Company (New molecular entities)
Reformulations (16 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
KIRSTY
BIOCON BIOLOGICS INC
T5 2025
LYUMJEV
Eli Lilly
T5 2020
SEMGLEE
Viatris
T5 2020
GVOKE VIALDX
XERIS
T3 2019
BAQSIMI
AMPHASTAR PHARMS INC
T3 2019
MYXREDLIN
Baxter
T5 2019
ADMELOG
SANOFI-AVENTIS US
T5 2017
ADMELOG SOLOSTAR
SANOFI-AVENTIS US
T5 2017
FIASP PENFILL
Novo Nordisk
T5 2017
FIASP
Novo Nordisk
T5 2017
FIASP FLEXTOUCH
Novo Nordisk
T5 2017
FLOLIPID
SALERNO PHARMS
T3 2016
AFREZZA
MANNKIND
T5 2014
VASCEPA
AMARIN PHARMS
T5 2012
VYTORIN
Merck
T4 2004
PITOCIN
PH HEALTH
T5 1980
Generic Drugs (4 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs